Start from a saved view, or filter by area, exchange and headquarters. Each row shows the pipeline, its most advanced asset and the next readout on record.
Lists by late-stage drug kind: biologics, small molecules, cell and gene therapies, RNA and oligonucleotide drugs, peptide drugs.
1457 of 1457 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Indapta Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | IDP-023Phase 1/2 · Multiple Myeloma | None on record | — | — | — | — |
Indication BioSciencePrivate | 1 asset: 1 Ph 1 | Atorvo+Phase 1 · Atherosclerotic Cardiovascular DiseaseWeak signal | None on record | — | — | — | — |
InduPro, Inc.Private | 1 asset: 1 Ph 2 | IDP-001Phase 1/2 · Non-Small Cell Lung Cancer | Jun 2028IDP-001 · Phase 1/2 | — | — | — | — |
Inhatarget TherapeuticsPrivate | 1 asset: 1 Ph 2 | CIS-DPIPhase 1/2 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
InnoMedica Schweiz AGPrivate | 1 asset: 1 Ph 2 | TalineurenPhase 2 · Parkinson's DiseasePartial signal | Dec 2027Talineuren · Phase 2 | — | — | — | — |
Innopeutics CorporationPrivate | 1 asset: 1 Ph 1 | IPS101APhase 1 · Parkinson's Disease | 30 Jun 2028IPS101A · Phase 1 | — | — | — | — |
Innovo TherapeuticsPrivate | 1 asset: 1 Ph 1 | INV-101Phase 1 · Ulcerative ColitisWeak signal | None on record | — | — | — | — |
| 1 asset: 1 Ph 1 | DUVAXPhase 1 · Alzheimer's Disease | 1 Apr 2027DUVAX · Phase 1 | — | — | — | — | |
Intas PharmaceuticalsPrivate | 3 assets: 2 Ph 3, 1 other | HD204Phase 3 · Non-Small Cell Lung CancerReliable signal | 30 Dec 2026Serplulimab · Phase 1 | — | — | — | — |
Integro TheranosticsPrivate | 1 asset: 1 Ph 2 | Cronexitide lanocianinePhase 2 · Non-Small Cell Lung Cancer | Jun 2027Cronexitide lanocianine · Phase 2 | — | — | — | — |
Intra-Cellular TherapiesPrivate | 2 assets: 1 approved, 1 Ph 3 | DeulumateperonePhase 3 · Generalized Anxiety Disorder | 16 Mar 2027Deulumateperone · Phase 2 | — | — | — | — |
IntralytixPrivate | 1 asset: 1 Ph 2 | EcoActivePhase 1/2 · Crohn's Disease | None on record | — | — | — | — |
Invenux, LLCPrivate | 1 asset: 1 Ph 1 | SCD-101Phase 1 · Sickle Cell Disease | None on record | — | — | — | — |
InxMedPrivate | 1 asset: 1 Ph 3 | IfebemtinibPhase 3 · Non-Small Cell Lung Cancer | 24 Mar 2027Ifebemtinib · Phase 2 | — | — | — | — |
Io TherapeuticsPrivate | 1 asset: 1 Ph 2 | IRX4204Phase 2 · PsoriasisWeak signal | None on record | — | — | — | — |
iOncturaPrivate | 1 asset: 1 Ph 2 | roginolisibPhase 2 · Uveal Melanoma | Jan 2027roginolisib · Phase 1/2 | — | — | — | — |
Iperboreal PharmaPrivate | 1 asset: 1 Ph 2 | PolyCorePhase 1/2 · Heart Failure | Dec 2026PolyCore · Phase 1/2 | — | — | — | — |
| 1 asset: 1 Ph 1 | iQ-007Phase 1 · Epilepsy | None on record | — | — | — | — | |
| 1 asset: 1 Ph 2 | NouvNeu001Phase 2 · Parkinson's Disease | Dec 2026NouvNeu001 · Phase 2 | — | — | — | — | |
Istituto Gentili S.R.L.Private | 1 asset: 1 Ph 3 | SugemalimabPhase 3 · Non-Small Cell Lung CancerReliable signal | Dec 2029Sugemalimab · Phase 3 | — | — | — | — |
Italfarmaco S.p.A.Private | 1 asset: 1 approved | Approved assets only | Dec 2026Givinostat · Phase 2 | — | — | — | — |
ITM Oncologics GmbHPrivate | 1 asset: 1 Ph 2 | 177Lu-DPI-4452Phase 1/2 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
J Ints BioPrivate | 1 asset: 1 Ph 2 | JIN-A02Phase 1/2 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
JanssenPrivate | 2 assets: 1 approved, 1 Ph 2 | LCB84Phase 1/2 · Non-Small Cell Lung Cancer | Jan 2027LCB84 · Phase 1/2 | — | — | — | — |
Jecho BiopharmaceuticalsPrivate | 1 asset: 1 Ph 2 | JL18008Phase 1/2 · HIVWeak signal | 12 Feb 2027JL18008 · Phase 1/2 | — | — | — | — |
Jeil PharmaceuticalPrivate | 1 asset: 1 Ph 3 | Pioglitazone (JT-001)Phase 3 · Type 2 DiabetesReliable signal | None on record | — | — | — | — |
JemincarePrivate | 2 assets: 1 Ph 3, 1 Ph 2 | JMKX001899Phase 3 · Non-Small Cell Lung Cancer | 31 Dec 2027JMKX001899 · Phase 3 | — | — | — | — |
| 2 assets: 1 Ph 3, 1 Ph 1 | VCT220Phase 3 · ObesityReliable signal | 1 Jul 2027VCT220 · Phase 2 | — | — | — | — | |
| 2 assets: 1 Ph 3, 1 Ph 1 | ACC017Phase 3 · HIVPartial signal | 30 Jun 2027ACC017 · Phase 1/2 | — | — | — | — | |
| 2 assets: 2 Ph 3 | LimertinibPhase 3 · Non-Small Cell Lung CancerReliable signal | Dec 2026ASKC202 · Phase 1 | — | — | — | — | |
| 1 asset: 1 Ph 3 | FHND9041Phase 3 · Non-Small Cell Lung Cancer | None on record | — | — | — | — | |
| 1 asset: 1 Ph 3 | GS101Phase 3 · Atopic Dermatitis | Apr 2027GS101 · Phase 3 | — | — | — | — | |
| 1 asset: 1 Ph 3 | TH-SC01Phase 3 · Crohn's DiseaseWeak signal | 28 Dec 2026TH-SC01 · Phase 3 | — | — | — | — | |
| 1 asset: 1 Ph 3 | SumecigrelPhase 3 · Atherosclerotic Cardiovascular DiseasePartial signal | 30 Dec 2026Sumecigrel · Phase 3 | — | — | — | — | |
Jiangsu Vcare PharmatechPrivate | 1 asset: 1 Ph 3 | VC005Phase 3 · Atopic Dermatitis | None on record | — | — | — | — |
Jiangxi Kvvit PharmaceuticalPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
| 1 asset: 1 Ph 3 | janagliflozinPhase 3 · Type 2 DiabetesReliable signal | 31 Dec 2027janagliflozin · Approved | — | — | — | — | |
Jina PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | nanosomal tacrolimusPhase 2 · Ulcerative Colitis | None on record | — | — | — | — |
JMackem Co., Ltd.Private | 1 asset: 1 Ph 1 | AJH-2947Phase 1 · Diabetic Peripheral Neuropathic PainPartial signal | None on record | — | — | — | — |
JS InnoMed HoldingsPrivate | 1 asset: 1 Ph 1 | VIC-1911Phase 1 · Non-Small Cell Lung CancerWeak signal | None on record | — | — | — | — |
Juno Therapeutics, Inc.Private | 1 asset: 1 Ph 3 | Arlocabtagene autoleucelPhase 3 · Multiple MyelomaWeak signal | 30 Dec 2027Arlocabtagene autoleucel · Phase 3 | — | — | — | — |
K36 Therapeutics, Inc.Private | 1 asset: 1 Ph 1 | GintemetostatPhase 1 · Multiple Myeloma | 31 Dec 2027Gintemetostat · Phase 1 | — | — | — | — |
Kadmon CorporationPrivate | 1 asset: 1 approved | Approved assets only | 26 Jan 2027Belumosudil · Phase 1 | — | — | — | — |
Kahr MedicalPrivate | 1 asset: 1 Ph 2 | DSP107Phase 2 · Colorectal Cancer | None on record | — | — | — | — |
Kalbe Genexine BiologicsPrivate | 1 asset: 1 Ph 3 | SerplulimabPhase 3 · Non-Small Cell Lung CancerReliable signal | 30 Dec 2026Serplulimab · Phase 1 | — | — | — | — |
KaliVir ImmunotherapeuticsPrivate | 1 asset: 1 Ph 1 | VET3-TGIPhase 1 · Non-Small Cell Lung Cancer | 30 Sep 2027VET3-TGI · Phase 1 | — | — | — | — |
Kamau Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | Nula-celPhase 1/2 · Sickle Cell Disease | 31 Dec 2026Nula-cel · Phase 1/2 | — | — | — | — |
Kariya PharmaceuticalsPrivate | 1 asset: 1 Ph 1 | KP405Phase 1 · Parkinson's DiseasePartial signal | None on record | — | — | — | — |
Kelonia Therapeutics, Inc.Private | 1 asset: 1 Ph 1 | KLN-1010Phase 1 · Multiple Myeloma | Mar 2027KLN-1010 · Phase 1 | — | — | — | — |
Kenai TherapeuticsPrivate | 1 asset: 1 Ph 2 | RNDP-001Phase 1/2 · Parkinson's Disease | Sep 2027RNDP-001 · Phase 1/2 | — | — | — | — |
Kestrel TherapeuticsPrivate | 1 asset: 1 Ph 1 | KST-6051Phase 1 · Non-Small Cell Lung Cancer | Apr 2028KST-6051 · Phase 1 | — | — | — | — |
Keystone Nano, IncPrivate | 1 asset: 1 Ph 1 | Ceramide NanoLiposome (Ceraxa)Phase 1 · Acute Myeloid Leukemia | 30 Jan 2027Ceramide NanoLiposome (Ceraxa) · Phase 1 | — | — | — | — |
Kibow PharmaPrivate | 1 asset: 1 Ph 3 | KT-301Phase 2/3 · Chronic Kidney Disease | None on record | — | — | — | — |
Kinaset TherapeuticsPrivate | 1 asset: 1 Ph 2 | frevecitinibPhase 2 · AsthmaWeak signal | 30 Nov 2027frevecitinib · Phase 2 | — | — | — | — |
Kind PharmaceuticalsPrivate | 1 asset: 1 Ph 3 | AND017Phase 3 · Chronic Kidney DiseasePartial signal | Dec 2026AND017 · Phase 2 | — | — | — | — |
Kindeva Drug DeliveryPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Kither BiotechPrivate | 1 asset: 1 Ph 2 | KIT2014Phase 1/2 · Chronic Obstructive Pulmonary Disease | 31 Mar 2027KIT2014 · Phase 1/2 | — | — | — | — |
Kivu Bioscience Inc.Private | 1 asset: 1 Ph 1 | KIVU-107Phase 1 · Non-Small Cell Lung Cancer | 31 Mar 2028KIVU-107 · Phase 1 | — | — | — | — |
Klinge Biopharma GmbHPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
| 1 asset: 1 Ph 1 | KS101Phase 1 · Alzheimer's Disease | None on record | — | — | — | — | |
Kowa Company, Ltd.Private | 3 assets: 2 Ph 3, 1 Ph 2 | AnagliptinPhase 3 · Type 2 DiabetesReliable signal | 31 Mar 2027Anagliptin · Approved | — | — | — | — |
Kumquat Biosciences Inc.Private | 1 asset: 1 Ph 1 | KQB368Phase 1 · Non-Small Cell Lung Cancer | Dec 2029KQB368 · Phase 1 | — | — | — | — |
Kure Cells, Inc.Private | 1 asset: 1 Ph 1 | UF-KURE-BCMAPhase 1 · Multiple Myeloma | 30 Sep 2028UF-KURE-BCMA · Phase 1 | — | — | — | — |
Kylonova (Xiamen) BiopharmaPrivate | 2 assets: 1 Ph 2, 1 Ph 1 | Kylo-11Phase 2 · Atherosclerotic Cardiovascular Disease | None on record | — | — | — | — |
Laboratoire X.OPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
| 2 assets: 2 approved | Approved assets only | Aug 2028Ponesimod · Phase 3 | — | — | — | — | |
Laboratoires SMB S.A.Private | 1 asset: 1 Ph 3 | PravafenixPhase 3 · Atherosclerotic Cardiovascular DiseasePartial signal | None on record | — | — | — | — |
Laboratoires TheaPrivate | 1 asset: 1 Ph 2 | KIO-301Phase 2 · Retinitis Pigmentosa | Aug 2027KIO-301 · Phase 2 | — | — | — | — |
Laboratoires ThéaPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
| 3 assets: 2 Ph 3, 1 Ph 2 | MB12Phase 3 · Non-Small Cell Lung CancerPartial signal | None on record | — | — | — | — | |
Laboratorios SanferPrivate | 1 asset: 1 Ph 3 | efpeglenatidePhase 3 · ObesityReliable signal | Nov 2027efpeglenatide · Phase 3 | — | — | — | — |
Laboratorios Stein S.A.Private | 1 asset: 1 Ph 3 | SugemalimabPhase 3 · Non-Small Cell Lung CancerReliable signal | Dec 2029Sugemalimab · Phase 3 | — | — | — | — |
LakeShore Biopharma Co., LtdPrivate | 2 assets: 1 Ph 3, 1 Ph 1 | PIKA Rabies VaccinePhase 3 · Rabies Prevention and Post-Exposure Prophylaxis | None on record | — | $15MMar 2025 | Ended Apr 2026 | $20M |
LAPIX TherapeuticsPrivate | 1 asset: 1 Ph 1 | LPX-TI641Phase 1 · Psoriatic Arthritis | None on record | — | — | — | — |
| 2 assets: 1 Ph 2, 1 Ph 1 | LT-002-158Phase 2 · Atopic Dermatitis | Jan 2028LT-002-158 · Phase 2 | — | — | — | — | |
Legacy Pharma Inc. SEZCPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
LEO PharmaPrivate | 6 assets: 5 approved, 1 Ph 2 | temtokibartPhase 2 · Atopic DermatitisReliable signal | 30 Sep 2027spesolimab · Phase 2 | — | — | — | — |
LIB TherapeuticsPrivate | 1 asset: 1 Ph 3 | LerodalcibepPhase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal | 31 Jul 2028Lerodalcibep · Phase 3 | — | — | — | — |
Libella Gene TherapeuticsPrivate | 1 asset: 1 Ph 1 | AAV-hTERTPhase 1 · Alzheimer's DiseaseWeak signal | None on record | — | — | — | — |
| 1 asset: 1 Ph 1 | NI-1801Phase 1 · Non-Small Cell Lung Cancer | None on record | — | — | — | — | |
Lighthouse PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | LHP588Phase 2 · Alzheimer's Disease | 31 Jan 2029LHP588 · Phase 2 | — | — | — | — |
Linde HealthcarePrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Lingyi Biotech Co., Ltd.Private | 1 asset: 1 Ph 1 | LY-N001Phase 1 · Parkinson's Disease | 7 Jul 2028LY-N001 · Phase 1 | — | — | — | — |
Linnaeus Therapeutics, Inc.Private | 1 asset: 1 Ph 3 | LNS8801Phase 2/3 · Melanoma | Feb 2029LNS8801 · Phase 2/3 | — | — | — | — |
Lmito TherapeuticsPrivate | 1 asset: 1 Ph 1 | LMT503Phase 1 · Ulcerative Colitis | 1 Sep 2027LMT503 · Phase 1 | — | — | — | — |
| 1 asset: 1 Ph 1 | LonitoclaxPhase 1 · Acute Myeloid Leukemia | Dec 2026Lonitoclax · Phase 1 | — | — | — | — | |
| 1 asset: 1 Ph 1 | LBT-3627Phase 1 · Parkinson's Disease | Feb 2027LBT-3627 · Phase 1 | — | — | — | — | |
| 2 assets: 1 approved, 1 Ph 3 | SerplulimabPhase 3 · Non-Small Cell Lung CancerReliable signal | 30 Dec 2026Serplulimab · Phase 1 | — | — | — | — | |
Luminary Therapeutics, Inc.Private | 2 assets: 1 Ph 2, 1 Ph 1 | LMY-920Phase 2 · Multiple Myeloma | Apr 2029LMY-922 · Phase 1 | — | — | — | — |
LyncBio TherapeuticsPrivate | 1 asset: 1 Ph 1 | LYNC-101Phase 1 · Ulcerative Colitis | 19 Mar 2027LYNC-101 · Phase 1 | — | — | — | — |
Lynk PharmaceuticalsPrivate | 2 assets: 1 Ph 3, 1 Ph 2 | ZemprocitinibPhase 3 · Atopic DermatitisReliable signal | Nov 2026Zemprocitinib · Phase 3 | — | — | — | — |
M8 PharmaceuticalsPrivate | 1 asset: 1 approved | Approved assets only | Dec 2026viloxazine · Phase 3 | — | — | — | — |
Mabpro, a.s.Private | 1 asset: 1 Ph 1 | CA9hu-1Phase 1 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
Mabwell Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | DISC-3405Phase 2 · Polycythemia Vera | Jun 2027DISC-3405 · Phase 1 | — | — | — | — |
mAbxience Research S.L.Private | 1 asset: 1 Ph 3 | MB12Phase 3 · Non-Small Cell Lung CancerPartial signal | None on record | — | — | — | — |
Mage BiologicsPrivate | 1 asset: 1 Ph 2 | MB-001Phase 1/2 · Ulcerative ColitisPartial signal | Jul 2028MB-001 · Phase 1/2 | — | — | — | — |
Mapi PharmaPrivate | 1 asset: 1 Ph 2 | Cariprazine long-acting injection (Mapi Pharma)Phase 1/2 · Schizophrenia | 31 Dec 2026Cariprazine long-acting injection (Mapi Pharma) · Phase 1/2 | — | — | — | — |
Marea TherapeuticsPrivate | 1 asset: 1 Ph 2 | MAR001Phase 2 · HypertriglyceridemiaWeak signal | Nov 2027MAR001 · Phase 2 | — | — | — | — |
Marengo Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | Invikafusp alfaPhase 1/2 · Non-Small Cell Lung Cancer | Jan 2027Invikafusp alfa · Phase 1/2 | — | — | — | — |
MaruhoPrivate | 3 assets: 2 approved, 1 Ph 2 | EVO756Phase 2 · MigrainePartial signal | Dec 2026nemolizumab · Phase 2 | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.